Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma
about
Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitorsA comprehensive overview of targeted therapy in metastatic renal cell carcinomaState of the science: an update on renal cell carcinomaTumor refractoriness to anti-VEGF therapyCancer-Associated Myeloid Regulatory CellsMarkers of Response to Antiangiogenic Therapies in Colorectal Cancer: Where Are We Now and What Should Be Next?Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlookCompensatory angiogenesis and tumor refractorinessKidney cancerIn vitro and in vivo models for analysis of resistance to anticancer molecular therapiesIndividualising treatment choices in a crowded treatment algorithmCirculating biomarkers in advanced renal cell carcinoma: clinical applicationsTargeting the tumor vasculature to enhance T cell activityCarcinoma-derived interleukin-8 disorients dendritic cell migration without impairing T-cell stimulationThe CXCL8-CXCR1/2 pathways in cancerLXY6090 - a novel manassantin A derivative - limits breast cancer growth through hypoxia-inducible factor-1 inhibitionRenal cell carcinoma.Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracyEvaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy.Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial.The role of CXC-chemokine receptor CXCR2 and suppressor of cytokine signaling-3 (SOCS-3) in renal cell carcinoma.Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials.Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated 18F-Fluorodeoxyglucose (18F-FDG) positron emission tomography/magnetic resonance imaging (PET/MRI); The REMAP studyAnti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapyResistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression.The role of angiopoietins as potential therapeutic targets in renal cell carcinoma.Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma.Mesenchymal stem cell-induced doxorubicin resistance in triple negative breast cancer.Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in Clear - Cell Renal Cell Carcinoma (ccRCC)Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling.Low molecular weight hyaluronan-pulsed human dendritic cells showed increased migration capacity and induced resistance to tumor chemoattraction.PRKX, TTBK2 and RSK4 expression causes Sunitinib resistance in kidney carcinoma- and melanoma-cell lines.Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy.Autotaxin-lysophosphatidic acid signaling axis mediates tumorigenesis and development of acquired resistance to sunitinib in renal cell carcinoma.A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528Renal cancer biomarkers: the promise of personalized careChallenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies.Identifying resistance mechanisms against five tyrosine kinase inhibitors targeting the ERBB/RAS pathway in 45 cancer cell lines.Biomarkers for anti-angiogenic therapy in cancer.
P2860
Q21184033-E16E801C-5DAB-46E7-AECC-9340DF2C6945Q24606852-0C9EBF0B-82D4-42AD-912A-B9BA861B92FBQ24630685-41B207F2-93BC-4488-AC6C-316FA500025BQ26747678-B45D631A-CEFD-43A3-86D9-807E70CA537AQ26750382-38C384DC-AD68-455D-88BE-EEDC7DB203A9Q26752752-B025CE15-E327-473F-8391-15F36A0DC9D2Q26823035-A4DB7F56-E965-4FC7-BC0C-B747F6717095Q26851916-40D0ED64-B925-4CD3-9CEA-4C3572607CF0Q26866709-FE7AB1E3-AF72-4C3F-89B7-DFE68C6DD85DQ27014174-A9949EB2-0F2B-4A6D-8DA3-D0A991880A79Q27023669-5F85BDD6-6871-4072-BBDB-1DAC5C0847BFQ27023770-596FEB3D-D56F-4912-BD0B-72E0F36436A0Q27026329-791740CB-D9AE-46A7-B854-75CA9D578D24Q27349546-6731FE5D-15FB-4810-86C8-524C5823C68FQ28075994-66654846-E08F-4021-AD8E-9723599DD935Q28828209-14F64687-E60E-4724-901F-C090E4658B1DQ30235364-391F000C-C634-4299-95D8-177FF1866686Q30563774-65BD2D3A-9EEE-43E4-A0C2-58439413FC3BQ30663984-8A5147F9-CF47-483C-BFF4-137C7E18B765Q33439523-56D53BF9-6F1B-4118-9D5C-09A76395F0F3Q33589279-EAC6F15F-79CD-4F23-8027-0A84B95AB471Q33633431-F111F484-73C6-4384-9F6F-1C48F6A4B416Q33755947-1E39FFCE-933B-4ACE-9F26-EA758BCE725AQ33770680-477A6565-4BBC-4086-B3F7-E32CF39B398DQ33828409-413B96FB-5128-428D-95E1-6069DAE2690CQ33895119-E4AFEE76-9ED9-4D45-9C27-86FAB5C8B31BQ33912405-154F9879-EF20-49A1-91A1-B21A34BE7BBCQ33960788-439FA870-E63A-44F0-8F2D-3D05955A30F3Q34012393-59EA40B2-AA57-4A77-81C2-643A3DA75B2EQ34077272-1C14CB7C-EC4F-4B5B-B99F-0FEE34D789E3Q34205907-7745D844-0804-49F3-9622-7F823463355FQ34216061-309FAA22-91DD-41B8-901E-D57702066916Q34226634-CED9D92E-3955-43CA-9925-21C095C9E4F9Q34300621-043253DF-4727-42FE-8409-568318B35CF8Q34314916-FE54B025-E261-4E40-9098-05A55BE554FDQ34322552-E4370D3D-38F9-4B96-9121-440247CF070AQ34422845-2A241FD4-C711-47BC-B06D-17231D59A224Q34627828-5FC48BE8-AD98-4048-ADA1-387AF537C39FQ34651354-EE2F50C5-0D6C-43F2-90FC-673D214B407BQ34695003-8B9460FB-C49F-45B3-9253-B1D97E617E79
P2860
Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Interleukin-8 mediates resista ...... itinib in renal cell carcinoma
@en
Interleukin-8 mediates resista ...... tinib in renal cell carcinoma.
@nl
type
label
Interleukin-8 mediates resista ...... itinib in renal cell carcinoma
@en
Interleukin-8 mediates resista ...... tinib in renal cell carcinoma.
@nl
prefLabel
Interleukin-8 mediates resista ...... itinib in renal cell carcinoma
@en
Interleukin-8 mediates resista ...... tinib in renal cell carcinoma.
@nl
P2093
P2860
P1433
P1476
Interleukin-8 mediates resista ...... itinib in renal cell carcinoma
@en
P2093
Brian I Rini
Chao-Nan Qian
David Petillo
Kyle A Furge
Richard Kahnoski
P2860
P304
P356
10.1158/0008-5472.CAN-09-3965
P407
P577
2010-01-26T00:00:00Z